Solvonis Therapeutics Plc

As of December 31, 2025, SOLVONIS THERAPEUTICS PLC carries a market capitalization of 23.83M, placing it among publicly traded companies globally. Its enterprise value stands at 21.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SOLVONIS THERAPEUTICS PLC's next confirmed earnings release is scheduled for June 30, 2027.

As of December 31, 2025, SOLVONIS THERAPEUTICS PLC has 6.81B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, SOLVONIS THERAPEUTICS PLC maintains a current ratio of 4.00, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.

As of the close on October 21, 2026, SOLVONIS THERAPEUTICS PLC's stock has declined approximately 82.22% over the past 52 weeks.

As of December 31, 2025, SOLVONIS THERAPEUTICS PLC holds 2.32M in cash and equivalents against 101,056.38 in total debt, resulting in a net debt position of -2.22M. Total book value stands at 8.34M, with working capital of 1.94M providing operational flexibility.